By: IPP Bureau
Last updated : August 11, 2025 12:27 pm
Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus
Global pharma major Lupin Limited (Lupin) today announced the launch of Glucagon for Injection USP, 1mg/vial packaged in an emergency kit in the United States.
Glucagon for Injection USP, 1mg/vial packaged in an emergency kit is bioequivalent to Glucagon for Injection, 1 mg/vial of Eli Lilly and Company. Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus and as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients.
Glucagon for Injection USP, 1mg/vial packaged in an emergency kit had an estimated annual sale of USD 122 million in the U.S. (IQVIA MAT June 2025).